REVOLUTIONARY WOUND TREATMENT
Approximately 2 million Americans develop a diabetic foot ulcer each year.
Within 5 years of ulceration, over 50% die and 5% lose a limb. Diabetic foot
ulcers cost the U.S. healthcare system $130 billion annually, require significant
patient self-management in terms of daily wound care and ambulation
restrictions, and can result in devastating function impact if a major (above- or
below-knee) amputation is required. Patients often fear major amputation from
diabetic foot ulcers more than death. Source
The worldwide diabetic foot ulcer challenge is huge where a number of
countries a much higher rate of incidences than the USA. The World Health
Organization has reported that the estimated number of patients with diabetes
was nearly 425 million in 2017, consequently, increasing the number of
diabetes-related complications. Studies have reported that the 5-year survival
rate in major lower extremity amputation in the diabetes population is
estimated at less than 50%. Source
Rural patients with diabetic foot ulcers currently face 50% higher odds of major
(above-ankle) amputation and 40% higher odds of death than their urban
counterparts. a health disparity identified by Dr. Meghan Brennan’s team and others.
Over 70% of Wisconsin residents live in rural areas, making this a particularly
important topic to address in our state. Source
The Medex47 product does not require a prescription and can be applied with
ease without the help of a health care professional.
Product Uniqueness
The market place has a number of silver based products utilizing nano-particals
of silver that leak silver ions over time. We are unique in that we are able to
infuse our product directly with a high level of silver ions that effect healing
immediately upon contact with a diabetic ulcer. There is no need to wait for the
slow release of ions from the nano-particles.
In addition to diabetic foot ulcers, our product is effective on burns, skin
conditions and wounds in general although these other applications are not
included in our starting target market.
Approximately 2 million
Americans develop a diabetic foot
ulcer each year. Within 5 years of
ulceration, over 50% die and 5%
lose a limb. Diabetic foot ulcers
cost the U.S. healthcare system
$130 billion annually, require
significant patient self-
management in terms of daily
wound care and ambulation
restrictions, and can result in
devastating function impact if a
major (above- or below-knee)
amputation is required. Patients
often fear major amputation from
diabetic foot ulcers more than
death. Source
The worldwide diabetic foot ulcer
challenge is huge where a number
of countries a much higher rate of
incidences than the USA. The
World Health Organization has
reported that the estimated
number of patients with diabetes
was nearly 425 million in 2017,
consequently, increasing the
number of diabetes-related
complications. Studies have
reported that the 5-year survival
rate in major lower extremity
amputation in the diabetes
population is estimated at less
than 50%. Source
Rural patients with diabetic foot
ulcers currently face 50% higher
odds of major (above-ankle)
amputation and 40% higher odds
of death than their urban
counterparts. a health disparity
identified by Dr. Meghan Brennan’s team
and others. Over 70% of
Wisconsin residents live in rural
areas, making this a particularly
important topic to address in our
state. Source
The Medex47 product does not
require a prescription and can be
applied with ease without the help
of a health care professional.
Product Uniqueness
The market place has a number of
silver based products utilizing
nano-particals of silver that leak
silver ions over time. We are
unique in that we are able to
infuse our product directly with a
high level of silver ions that effect
healing immediately upon contact
with a diabetic ulcer. There is no
need to wait for the slow release
of ions from the nano-particles.
In addition to diabetic foot ulcers,
our product is effective on burns,
skin conditions and wounds in
general although these other
applications are not included in
our starting target market.
REVOLUTIONARY WOUND
TREATMENT
